Ponatinib (AP24534)

Name: Ponatinib (AP24534)
Brand: Selleck Chemicals
SKU: S1490
Rating: 5 (98 reviews)

For research use only.

Catalog No.S1490

98 publications

CAS No. 943319-70-8

Ponatinib (AP24534) is a novel, potent multi-target inhibitor of Abl, PDGFRα, VEGFR2, FGFR1 and Src with IC50 of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM and 5.4 nM in cell-free assays, respectively. Ponatinib (AP24534) inhibits autophagy.

Selleck's Ponatinib (AP24534) has been cited by 98 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(4):431-443

PubMed: 31543464 ( click the link to review the publication )

Nature, 2016, 30;534(7609):647-51.

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2016, 6(7):727-39

PubMed: 27231123 ( click the link to review the publication )

Nature, 2015, 10.1038/nature14329

PubMed: 25970250 ( click the link to review the publication )

Cancer Cell, 2014, 26(2):207-21

PubMed: 25065853 ( click the link to review the publication )

Cancer Cell, 2012, 22(5):656-67

PubMed: 23153538 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.32924

PubMed: 32064608 ( click the link to review the publication )

FASEB J, 2020, 34(3):3773-3791

PubMed: 31945226 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

J Infect Dis, 2020, 3;jiaa295

PubMed: 32492702 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Front Pharmacol, 2020, 30;11:543

PubMed: 32425788 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):592

PubMed: 32580713 ( click the link to review the publication )

Nature, 2020, 583(7818):845-851

PubMed: 32699415 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2020, 1864(4):129507

PubMed: 31881245 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04022-x

PubMed: 31901955 ( click the link to review the publication )

Commun Biol, 2020, 3(1):18

PubMed: 31925328 ( click the link to review the publication )

Front Cell Dev Biol, 2020, 8:408

PubMed: 32596239 ( click the link to review the publication )

Cold Spring Harb Mol Case Stud, 2020, 1;6(2) pii: a004838

PubMed: 31980503 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2701

PubMed: 31221965 ( click the link to review the publication )
Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 26(1):65-78

PubMed: 30605687 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Protein Cell, 2019, 10(3):161-177

PubMed: 29667003 ( click the link to review the publication )

Br J Cancer, 2019, 120(6):612-620

PubMed: 30792533 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(11):1985-1996

PubMed: 31308077 ( click the link to review the publication )

FEBS J, 2019, 286(22):4443-4472

PubMed: 31155838 ( click the link to review the publication )

Front Oncol, 2019, 9:103

PubMed: 30931252 ( click the link to review the publication )

J Proteome Res, 2019, 18(1):522-534

PubMed: 30540191 ( click the link to review the publication )

Cell Cycle, 2019, 18(18):2307-2322

PubMed: 31349760 ( click the link to review the publication )

Transl Oncol, 2019, 12(9):1221-1228

PubMed: 31276961 ( click the link to review the publication )

Leuk Lymphoma, 2019, 60(1):189-199

PubMed: 29741440 ( click the link to review the publication )

Exp Dermatol, 2019, 10.1111/exd.14010

PubMed: 31338879 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2019, 46(2):126-136

PubMed: 30251267 ( click the link to review the publication )

Leukemia, 2019, 33(8):1964-1977

PubMed: 30842608 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(8):1932-1943

PubMed: 29440177 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30572654 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(7):1405-1415

PubMed: 29695637 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Respir Res, 2018, 19(1):120

PubMed: 29921306 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(65):32496-32506

PubMed: 30197758 ( click the link to review the publication )

Sci Adv, 2018, 4(11):eaau0731

PubMed: 30417093 ( click the link to review the publication )
Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28199182 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):8

PubMed: 28069043 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-17-0008

PubMed: 28500237 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1729-1738

PubMed: 28619758 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Leuk Lymphoma, 2017, 58(6):1455-1467

PubMed: 27733071 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Sci Rep, 2017, 7(1):15219

PubMed: 29123157 ( click the link to review the publication )

Gut, 2016, 10.1136/gutjnl-2015-310382

PubMed: 26953272 ( click the link to review the publication )

Blood, 2016, 28;127(17):2131-43

PubMed: 26864341 ( click the link to review the publication )

Hepatology, 2016, 64(2):488-500

PubMed: 27015352 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1273-1281

PubMed: 27068398 ( click the link to review the publication )

Leukemia, 2016, 30(7):1493-501

PubMed: 27044711 ( click the link to review the publication )

Cancer Sci, 2016, 107(2):140-8

PubMed: 26583567 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Oncotarget, 2016, 7(47):78083-78094

PubMed: 27801667 ( click the link to review the publication )

Tumour Biol, 2016, 37(2):2365-78

PubMed: 26373734 ( click the link to review the publication )

Genes Chromosomes Cancer, 2016, 55(1):60-8

PubMed: 26391436 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Sci Transl Med, 2015, 7(298):298ra119

PubMed: 26223302 ( click the link to review the publication )

Nat Commun, 2015, 6:7002

PubMed: 25926053 ( click the link to review the publication )

Leukemia, 2015, 29(5)

PubMed: 25394714 ( click the link to review the publication )
Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

J Med Chem, 2015, 58(23):9228-37

PubMed: 26562217 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1767

PubMed: 25996294 ( click the link to review the publication )

Toxicol Sci, 2015, 143(1):147-55

PubMed: 25304212 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120841

PubMed: 25803811 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(2):133-44

PubMed: 24463606 ( click the link to review the publication )

Sci Transl Med, 2014, 6(261):261ra152

PubMed: 25378644 ( click the link to review the publication )

Blood, 2014, 123(21):3296-304

PubMed: 24723681 ( click the link to review the publication )

Genome Biol, 2014, 15(8):428

PubMed: 25315765 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1321173111

PubMed: 24550512 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )

Structure, 2014, 22(12):1764-74

PubMed: 25465127 ( click the link to review the publication )

Oncol Rep, 2014, 31(4):1605-12

PubMed: 24481648 ( click the link to review the publication )

Thrombo Res, 2014, 135(1):155-60

PubMed: 25527332 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 446(1):54-60

PubMed: 24565842 ( click the link to review the publication )

Oncoscience, 2014, 1(1):57-68

PubMed: 25593988 ( click the link to review the publication )

J Thorac Oncol, 2014, 9(9):1316-23

PubMed: 25122427 ( click the link to review the publication )

Harvard University, 2014, Rachel Grace Liao

PubMed: ( click the link to review the publication )

Clin Cancer Res, 2013, 19(6):1422-32

PubMed: 23319824 ( click the link to review the publication )

Cancer Res, 2013, 73(16):5195-205

PubMed: 23786770 ( click the link to review the publication )

Neoplasia, 2013, 15(8):975-88

PubMed: 23908597 ( click the link to review the publication )

Curr Cancer Drug Targets, 2012, 12(5):505-21

PubMed: 22483156 ( click the link to review the publication )
Exp Hematol, 2012, 41(4):335-45.e3

PubMed: 23287417 ( click the link to review the publication )

Mol Genet Metab, 2010, 100(4):309-15

PubMed: 20554235 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description

Targets

Abl ^[1] (Cell-free assay)	PDGFRα ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)	FGFR1 ^[1] (Cell-free assay)	c-Src ^[1] (Cell-free assay)	View More
0.37 nM	1.1 nM	1.5 nM	2.2 nM	5.4 nM	View More

In vitro

AP24534 potently inhibits native Abl, Abl^T315I, and other clinically important Abl kinase domain mutants with IC50 of 0.30 nM–2 nM. AP24534 doesn't inhibit Aurora kinase family members, nor does it inhibit insulin receptor or CDK2/cyclin E. AP24534 inhibits proliferation of Ba/F3 cells expressing Bcr-Abl with IC50 of 0.5 nM, as well as Ba/F3 cells expressing a range of Bcr-Abl mutants with IC50 of 0.5 nM–36 nM. The inhibition of proliferation by AP24534 is correlated with induction of apoptosis. ^[1-2] In leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors, AP24534 potently inhibits receptor phosphorylation and cellular proliferation with IC50 of 0.3 nM to 20 nM. In MV4-11 (FLT3-ITD(+/+)) but not RS4;11 (FLT3-ITD(–/–)) AML cells, AP24534 inhibits FLT3 signaling and induced apoptosis at less than 10 nM. AP24534 inhibits viability of primary leukemic blasts from a FLT3-ITD positive AML patient with IC50 of 4 nM but not those from patients with AML expressing native FLT3. ^[3] In Ba/F3 cells engineered to express activated FGFR1-4, AP24534 potently inhibits FGFR-mediated signaling and viability with IC50 lower than 40 nM. In cell lines representing multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon), and containing FGFRs dysregulated by a variety of mechanisms, AP24534 inhibits FGFR-mediated signaling with IC50 less than 40 nM and inhibits cell growth with IC50 of 7 nM–181 nM. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
EoL-1-cell	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nCS2lEPTB;MD6wNFAxODByM{W5JO69VQ>?	NFu0[3NUSU6JRWK=
MV-4-11	NITpdHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\QTWM2OD1yLkCwNFA6PTZizszN	MXPTRW5ITVJ?
MEG-01	M1XpVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGe2WHRKSzVyPUCuNFAxOTJ6IN88US=>	MX3TRW5ITVJ?
LAMA-84	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMECwNVY2KM7:TR?=	M37TXnNCVkeHUh?=
CGTH-W-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmn2TWM2OD1yLkCwNVY6KM7:TR?=	Mo\6V2FPT0WU
KASUMI-1	MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnmNpVKSzVyPUCuNFAzOTdizszN	NVq0b2h[W0GQR1XS
BE-13	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Pk[2lEPTB;MD6wNFI2QSEQvF2=	NGn2NnlUSU6JRWK=
CTV-1	M{jvUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX3JR\|UxRTBwMEC1NlEh\|ryP	MXHTRW5ITVJ?
NKM-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHCTWM2OD1yLkCwOlU2KM7:TR?=	M334R3NCVkeHUh?=
MONO-MAC-6	NY\peIRuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zMOWlEPTB;MD6wNFg{PyEQvF2=	NXOyR4lSW0GQR1XS
A204	NH;MU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHO2VFJKSzVyPUCuNFEzOThizszN	MU\TRW5ITVJ?
GDM-1	NYD1SpNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXXL[mFDUUN3ME2wMlAyQDN\|IN88US=>	MXHTRW5ITVJ?
AN3-CA	MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETPSVVKSzVyPUCuNFE5PzNizszN	MX;TRW5ITVJ?
BL-70	NUjJd4xCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XQdWlEPTB;MD6wNlE6QSEQvF2=	MYrTRW5ITVJ?
Daudi	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMEK1N\|ch\|ryP	Mo[wV2FPT0WU
KU812	M1ztPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrUTWM2OD1yLkCyPFQ5KM7:TR?=	NXrkNJJVW0GQR1XS
KG-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDTTWM2OD1yLkCzNlk1KM7:TR?=	MXXTRW5ITVJ?
DOHH-2	NWPyd\|F5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoL0TWM2OD1yLkC0PFA{KM7:TR?=	M1vrRnNCVkeHUh?=
HuO9	NEHPV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMEW0OFgh\|ryP	NULobpFEW0GQR1XS
EB2	MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmX1TWM2OD1yLkC1OVc3KM7:TR?=	M2XGN3NCVkeHUh?=
G-402	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LhbmlEPTB;MD6wOlM1OSEQvF2=	MV;TRW5ITVJ?
SU-DHL-1	M4Pwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwME[zO\|kh\|ryP	MofJV2FPT0WU
NCI-H719	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMEe4PFgh\|ryP	M4H5fnNCVkeHUh?=
MLMA	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljSTWM2OD1yLkC5NFYh\|ryP	NVHmN\|l7W0GQR1XS
KM12	NEjWb45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGexO2JKSzVyPUCuNFk4OzdizszN	NETq[WxUSU6JRWK=
SUP-T1	NHq1SmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrJdmFKSzVyPUCuNFk6QDJizszN	Mli5V2FPT0WU
MZ1-PC	M3\XN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nNeGlEPTB;MD6xNVM{PiEQvF2=	Mn:yV2FPT0WU
MFE-296	NH7uWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXTTWM2OD1yLkGxPFM6KM7:TR?=	MXfTRW5ITVJ?
ALL-PO	NWjpTHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq5[m44UUN3ME2wMlEzPDR\|IN88US=>	NVKySo5bW0GQR1XS
GB-1	NGW3WIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPrOXVKSzVyPUCuNVI2OTJizszN	NV3hOXJGW0GQR1XS
SIG-M5	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGDu[VVKSzVyPUCuNVM{PyEQvF2=	NU\zZVFGW0GQR1XS
P30-OHK	NYjvW5ROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL6XJh6UUN3ME2wMlE2Pjd{IN88US=>	MmnmV2FPT0WU
NCI-H716	M2XOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMU[yOlYh\|ryP	M{HUfnNCVkeHUh?=
MPP-89	M3jUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVL6fVRnUUN3ME2wMlE3QTN\|IN88US=>	MUDTRW5ITVJ?
SF126	M{nNcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrUdHlIUUN3ME2wMlE4ODZ\|IN88US=>	MkPEV2FPT0WU
CTB-1	NVH4cm02T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknUTWM2OD1yLkG3N\|E3KM7:TR?=	NHziWHZUSU6JRWK=
CA46	M33tbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTBwMUe0PFkh\|ryP	NV\hTJVGW0GQR1XS
NCI-H520	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDuVWdqUUN3ME2wMlE4PzN{IN88US=>	Ml7FV2FPT0WU
CAL-85-1	NEn0epRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{Xu[WlEPTB;MD6xO\|kzPyEQvF2=	NGXkVHhUSU6JRWK=
NCI-H2342	M4\CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXTqVHFCUUN3ME2wMlE5PTd5IN88US=>	MXPTRW5ITVJ?
697	M2Pkdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMUi4O\|Eh\|ryP	NHX3[WdUSU6JRWK=
NY	NUTlT2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HU[WlEPTB;MD6xPVI5PyEQvF2=	M4PNdnNCVkeHUh?=
T98G	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFTV[m9KSzVyPUCuNVk{OThizszN	MUnTRW5ITVJ?
NCI-H1703	NYHLOXl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUS2UlV1UUN3ME2wMlE6PjF3IN88US=>	MnO4V2FPT0WU
NCI-H2087	NIjZNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M36xcWlEPTB;MD6yNFQ{QSEQvF2=	MXPTRW5ITVJ?
PF-382	M{X0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHn1VWxKSzVyPUCuNlA5PzNizszN	M4C0OHNCVkeHUh?=
HCT-116	M2DRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rNXmlEPTB;MD6yNVA3QSEQvF2=	NWGySod5W0GQR1XS
CAKI-1	NEnwZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXfMOnl1UUN3ME2wMlIyPjZ4IN88US=>	M4DrcnNCVkeHUh?=
CCF-STTG1	M2q3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMkK0O\|Uh\|ryP	NVPwSJhjW0GQR1XS
D-392MG	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvSTWM2OD1yLkKzNVc4KM7:TR?=	MmrvV2FPT0WU
RT-112	NVnXSVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlWwTWM2OD1yLkKzO\|k2KM7:TR?=	MmTUV2FPT0WU
MES-SA	MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWr0UmpNUUN3ME2wMlI1OTh5IN88US=>	NIr1cYJUSU6JRWK=
LC-2-ad	MkXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TiVmlEPTB;MD6yOFI3PSEQvF2=	MWnTRW5ITVJ?
NOS-1	NX7YZmN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkC5TWM2OD1yLkK0N\|Y4KM7:TR?=	NGfEXmtUSU6JRWK=
NALM-6	NEPpbXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMkW1OFMh\|ryP	MnnUV2FPT0WU
TE-15	NWT6Nox2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILob3BKSzVyPUCuNlYxQTFizszN	MUfTRW5ITVJ?
786-0	M1f0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XOeGlEPTB;MD6yOlIzQCEQvF2=	NIWwTlBUSU6JRWK=
IST-MES1	MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMk[4Nlkh\|ryP	MWHTRW5ITVJ?
KYSE-180	MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn6xTWM2OD1yLkK2PFkyKM7:TR?=	MlHLV2FPT0WU
YT	MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInwU\|BKSzVyPUCuNlY6PzRizszN	NVfUb2d3W0GQR1XS
A427	MnnDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTBwMkeyOlQh\|ryP	NE\Fc3lUSU6JRWK=
KYSE-450	NID1VGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwMkezNlkh\|ryP	M2rTcHNCVkeHUh?=
HuH-7	NUj6e5A5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYCxS49CUUN3ME2wMlI4PzZ\|IN88US=>	NH3jWGtUSU6JRWK=
CAS-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\FTWM2OD1yLkK4N\|A{KM7:TR?=	NWnvblk3W0GQR1XS
KURAMOCHI	NIWyTXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zsbGlEPTB;MD6yPFQyQSEQvF2=	M2OzPHNCVkeHUh?=
ACHN	NUnvZXgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NILWeW5KSzVyPUCuNlk{OjNizszN	MYTTRW5ITVJ?
HGC-27	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTBwMkmzOVMh\|ryP	NWfQcHVIW0GQR1XS
A172	M3HWc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonvTWM2OD1yLkK5OVc4KM7:TR?=	NV6x[\|cxW0GQR1XS
SNU-449	M3\rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfyTWM2OD1yLkK5PVY1KM7:TR?=	M3vhTnNCVkeHUh?=
SW982	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWmwOHNYUUN3ME2wMlI6QTd6IN88US=>	Mm[yV2FPT0WU
EFO-21	NXzX[XRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwM{C0NVEh\|ryP	MkDLV2FPT0WU
NCI-H2030	Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwM{GxOlQh\|ryP	NH\lXHBUSU6JRWK=
HT-144	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYK1OItCUUN3ME2wMlMyOjhizszN	MkLxV2FPT0WU
MFE-280	NEjWeWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3r0PGlEPTB;MD6zNVQ2OyEQvF2=	MVXTRW5ITVJ?
SK-LU-1	NYnxdXhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{myXWlEPTB;MD6zNVQ3PiEQvF2=	M1L3RnNCVkeHUh?=
NCI-H2052	NFn3U4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYS2c\|lrUUN3ME2wMlMyPDh2IN88US=>	M33rWXNCVkeHUh?=
SK-HEP-1	NV\WNm5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXiTWM2OD1yLkOzN\|Y5KM7:TR?=	MVTTRW5ITVJ?
QIMR-WIL	M1PRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwM{O0NlQh\|ryP	M2PZbnNCVkeHUh?=
A2780	NFu3OVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvBTWM2OD1yLkO0N\|A1KM7:TR?=	M{CxXHNCVkeHUh?=
ACN	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\td2tKSzVyPUCuN\|Q5PzNizszN	NFLiPJJUSU6JRWK=
BxPC-3	NWLy[5A3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwM{S5PFkh\|ryP	MV;TRW5ITVJ?
BCPAP	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nOfWlEPTB;MD6zOlAxOSEQvF2=	MnjRV2FPT0WU
HOP-62	NGfwUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwM{[xNFYh\|ryP	NYLhe3czW0GQR1XS
SW1710	M3LCZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwM{[0OVUh\|ryP	M1nuNXNCVkeHUh?=
OPM-2	NXnyUFhXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkK2TWM2OD1yLkO2OFc{KM7:TR?=	MUnTRW5ITVJ?
DBTRG-05MG	MlTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknyTWM2OD1yLkO4NFU1KM7:TR?=	NUnYfmx2W0GQR1XS
SK-MEL-24	NW\vPZd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwM{m3PVEh\|ryP	M1:4OnNCVkeHUh?=
8305C	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwM{m3PVMh\|ryP	M3uxbXNCVkeHUh?=
OVCAR-4	Mn\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLJTWM2OD1yLkSxOVg3KM7:TR?=	MorZV2FPT0WU
HLE	MoX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYS0[\|B3UUN3ME2wMlQyQDZizszN	NVH3VWtvW0GQR1XS
NCI-H747	M3XrSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrRTWM2OD1yLkSyNVM4KM7:TR?=	NInyUW1USU6JRWK=
SW780	NF;WXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn2TWM2OD1yLkSyN\|Q3KM7:TR?=	NXTTV5FsW0GQR1XS
KYSE-150	NHmwbGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4jVTWlEPTB;MD60NlQyPSEQvF2=	MlnwV2FPT0WU
H4	M2m5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3yfmlKSzVyPUCuOFI1PTFizszN	NGHUb2lUSU6JRWK=
SW1088	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\3Z4dKSzVyPUCuOFQ{QSEQvF2=	NYfw[GdpW0GQR1XS
SF268	NFfkOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvnTWM2OD1yLkS0PFYh\|ryP	NX[zdIFqW0GQR1XS
RT4	NX65[FFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzkTWM2OD1yLkS1NVEyKM7:TR?=	NHj3OXRUSU6JRWK=
NCI-H522	M{PufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFPJclNKSzVyPUCuOFUzPyEQvF2=	MmXWV2FPT0WU
LCLC-97TM1	M1\rTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jYU2lEPTB;MD60OlE6PSEQvF2=	NUS5d2dGW0GQR1XS
CAL-39	NXTN[YN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwNE[1NVkh\|ryP	MX7TRW5ITVJ?
CAL-120	NUfZS3MxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVrlTnRmUUN3ME2wMlQ4PjR\|IN88US=>	MV3TRW5ITVJ?
ESS-1	M{jBfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzQUppKSzVyPUCuOFc5OjFizszN	Mof0V2FPT0WU
KARPAS-45	Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEm4O4tKSzVyPUCuOFg6OzNizszN	M2jjT3NCVkeHUh?=
DU-4475	NEHSVoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIriSldKSzVyPUCuOFk2OTFizszN	MnPnV2FPT0WU
VMRC-RCZ	M3LLUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3NUVBKSzVyPUCuOFk6ODRizszN	MnH1V2FPT0WU
HOS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnZTWM2OD1yLkWwN\|Y2KM7:TR?=	M{nuSXNCVkeHUh?=
MOLT-16	M2fTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwNUG4NFgh\|ryP	M2LNUXNCVkeHUh?=
RPMI-6666	NXLzdIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojSTWM2OD1yLkWyNVM2KM7:TR?=	M3Xq[HNCVkeHUh?=
K052	MlHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTwUHRTUUN3ME2wMlUzOTRizszN	NInrWmlUSU6JRWK=
EHEB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHvNOXRKSzVyPUCuOVIyQDJizszN	NWf4eVBqW0GQR1XS
MFH-ino	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwNUKzOVEh\|ryP	NIPY[XRUSU6JRWK=
A4-Fuk	NVeybWY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwNUK1Nlgh\|ryP	MojoV2FPT0WU
SW1417	NFztSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXM[olKSzVyPUCuOVI4QDFizszN	MV\TRW5ITVJ?
DoTc2-4510	NYnBd2I3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1H6S2lEPTB;MD61OFk2QCEQvF2=	MoPqV2FPT0WU
TE-12	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLwTWM2OD1yLkW1O\|M2KM7:TR?=	NULndZJMW0GQR1XS
8-MG-BA	NXi5U4p4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX3SfYhXUUN3ME2wMlU3ODV4IN88US=>	Mo\UV2FPT0WU
ECC12	NHTadJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvubGRKSzVyPUCuOVY2PThizszN	Mk\rV2FPT0WU
CHL-1	NFHxb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTOTWM2OD1yLkW3OFY{KM7:TR?=	MnvvV2FPT0WU
LCLC-103H	NHHTfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPPbIJKSzVyPUCuOVg{PDRizszN	NGXITHhUSU6JRWK=
OS-RC-2	NUD4UopVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\3WmlEPTB;MD61PFM4QSEQvF2=	MmLPV2FPT0WU
RO82-W-1	M3LKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\nOmlEPTB;MD61PVYyPSEQvF2=	MoTDV2FPT0WU
A3-KAW	M3u3O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXiwTnZOUUN3ME2wMlYyPDZ5IN88US=>	NVPldYd{W0GQR1XS
NCCIT	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\CTWM2OD1yLk[xO\|E2KM7:TR?=	MV3TRW5ITVJ?
IST-SL2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\zPI1ZUUN3ME2wMlYzPTJ{IN88US=>	M1H6WnNCVkeHUh?=
GI-ME-N	NHrS[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwNkOwOlkh\|ryP	NVnFS5U3W0GQR1XS
ES6	NEjHfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofpTWM2OD1yLk[zNlk2KM7:TR?=	NU\OclUyW0GQR1XS
BL-41	NWDz[XRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j2dGlEPTB;MD62N\|M2OiEQvF2=	MU\TRW5ITVJ?
Ca-Ski	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PDSWlEPTB;MD62OFgyKM7:TR?=	NIOzbWVUSU6JRWK=
HOP-92	NEX1OXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUO5VW1VUUN3ME2wMlY2Pjd{IN88US=>	MnvIV2FPT0WU
SK-LMS-1	NELZPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwNk[0O{DPxE1?	M1PRN3NCVkeHUh?=
EW-13	NFPucodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwNk[3O\|kh\|ryP	M3HxZXNCVkeHUh?=
647-V	NETlbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTBwNkixOFgh\|ryP	M4TV[XNCVkeHUh?=
JiyoyeP-2003	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXizdZFtUUN3ME2wMlY6PzN6IN88US=>	MVjTRW5ITVJ?
WSU-NHL	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHCNmJKSzVyPUCuO\|A5QDdizszN	MoDNV2FPT0WU
U-698-M	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwN{GwOlMh\|ryP	NXrneWNMW0GQR1XS
HC-1	NW[wdXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTre3BlUUN3ME2wMlczPDB3IN88US=>	MVvTRW5ITVJ?
8505C	Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4n5Z2lEPTB;MD63Nlc1OSEQvF2=	NETk[VhUSU6JRWK=
HUTU-80	MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTJWIFlUUN3ME2wMlc{OzR7IN88US=>	NWXPPGZRW0GQR1XS
LB1047-RCC	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwN{O1N\|gh\|ryP	NHXNNJFUSU6JRWK=
GAMG	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILHZ2pKSzVyPUCuO\|M3PTNizszN	Ml3CV2FPT0WU
CAL-12T	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHaVZJUUUN3ME2wMlc{QDd5IN88US=>	NXHtVYpnW0GQR1XS
NCI-SNU-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXPTWM2OD1yLke3Nlc5KM7:TR?=	MWHTRW5ITVJ?
HTC-C3	M4XLS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoW1TWM2OD1yLke3OFUyKM7:TR?=	MlLxV2FPT0WU
HPAF-II	NV\6U5JCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;KU2lEPTB;MD63O\|UxOSEQvF2=	NEH1fGxUSU6JRWK=
KGN	M4T2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofaTWM2OD1yLke4NFgyKM7:TR?=	NH7aPINUSU6JRWK=
EFO-27	M3ixPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7pTI83UUN3ME2wMlc5PzN\|IN88US=>	M2jrc3NCVkeHUh?=
MEL-HO	M{PaWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjtdFVKSzVyPUCuO\|k1PDlizszN	M3rvcnNCVkeHUh?=
KYSE-270	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwOEC1Nlkh\|ryP	NYqwfYpNW0GQR1XS
NCI-H1755	NYTHdVNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXrOGlGUUN3ME2wMlgxPzF2IN88US=>	M4PHOXNCVkeHUh?=
MFM-223	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1[2VWlEPTB;MD64NVQxPyEQvF2=	NVfBSIVjW0GQR1XS
G-361	NX[zVolZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{nZcWlEPTB;MD64NVg6PyEQvF2=	MlvCV2FPT0WU
ETK-1	Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwOEK0OFEh\|ryP	M2PpSXNCVkeHUh?=
LU-99A	MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwOES3NFEh\|ryP	MnLrV2FPT0WU
IST-MEL1	M2HaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFP5TIxKSzVyPUCuPFU4OzJizszN	M1XB[XNCVkeHUh?=
L-540	NV64[YExT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3i5[GlEPTB;MD64OVgxOSEQvF2=	NGX4[4pUSU6JRWK=
U-2-OS	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULaPI1LUUN3ME2wMlg2QDR4IN88US=>	NWrSfldxW0GQR1XS
HT-1376	MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDYdGNKSzVyPUCuPFYxPTFizszN	NHjES\|BUSU6JRWK=
COLO-680N	NIniUplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHETHJ2UUN3ME2wMlg4QTN\|IN88US=>	M4jQZXNCVkeHUh?=
NCI-H1581	M4m5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTBwOEmyPVch\|ryP	M17QdnNCVkeHUh?=
HuCCT1	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEiwXpdKSzVyPUCuPFk2PDhizszN	M{\oXHNCVkeHUh?=
BB30-HNC	NF;nUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rpZWlEPTB;MD65NlQ3QSEQvF2=	M{fiOXNCVkeHUh?=
NCI-H2347	NF\0dnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LpdWlEPTB;MD65N\|I6OiEQvF2=	M4XQfnNCVkeHUh?=
G-401	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnUWo1yUUN3ME2wMlk{Pjl3IN88US=>	Moj1V2FPT0WU
NCI-H358	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTBwOUWwNVQh\|ryP	NHjCbodUSU6JRWK=
HCC1395	M3HUVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDTcZRLUUN3ME2wMlk2PDZzIN88US=>	MUXTRW5ITVJ?
J82	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlm4TWM2OD1yLkm1OVQ{KM7:TR?=	MXXTRW5ITVJ?
KE-37	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL0cnhKSzVyPUCuPVY{QDdizszN	MmrjV2FPT0WU
NOMO-1	NVv5bpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVy4Spl6UUN3ME2wMlk3PTZ2IN88US=>	NVLvSpFWW0GQR1XS
ML-2	MnzvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DyZmlEPTB;MD65PVc2KM7:TR?=	MlzPV2FPT0WU
SW872	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTBwOUm3O\|Uh\|ryP	MojoV2FPT0WU
KYSE-520	M1zmT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTFwMEC0PVQh\|ryP	MXnTRW5ITVJ?
HL-60	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4qyeGlEPTB;MT6wNFk4KM7:TR?=	M4L4WnNCVkeHUh?=
HDLM-2	MonOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjuN2hSUUN3ME2xMlAyOjV{IN88US=>	MXzTRW5ITVJ?
MIA-PaCa-2	NEnMZm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzOTWM2OD1zLkCxN\|c2KM7:TR?=	MXPTRW5ITVJ?
TCCSUP	NIT6OGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVe3PWp4UUN3ME2xMlAyPzN{IN88US=>	M4PBeHNCVkeHUh?=
SH-4	M2\rbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTmTWM2OD1zLkCyNlQ1KM7:TR?=	MonTV2FPT0WU
MG-63	NXPCeo9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33XOGlEPTB;MT6wNlYyPiEQvF2=	MUfTRW5ITVJ?
NB6	NYP3N4tWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPCTWM2OD1zLkCzNVA6KM7:TR?=	MVHTRW5ITVJ?
CAL-54	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrkWohKSzVyPUGuNFM6PTlizszN	MW\TRW5ITVJ?
DU-145	M4rTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzYTWM2OD1zLkC4NFc{KM7:TR?=	NXizUWZSW0GQR1XS
HCE-4	NETOOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTFwMEmyPFYh\|ryP	M3zKeHNCVkeHUh?=
U-266	NHjqRVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTFwMEm2N\|Mh\|ryP	Mk\LV2FPT0WU
HT-1197	NWnrSpVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvtOlZKSzVyPUGuNVE1OzhizszN	NUD5eFZKW0GQR1XS
EW-1	NIHWfm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjsUJNKSzVyPUGuNVQyOjhizszN	NGPIVpFUSU6JRWK=
MHH-NB-11	NYDWNW12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTFwMUWzOlgh\|ryP	NEm5PZZUSU6JRWK=
NCI-H2405	MoLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXjZnd2UUN3ME2xMlE3OTZizszN	MWPTRW5ITVJ?
COLO-668	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXOzZ3ZIUUN3ME2xMlE3PDlizszN	M2PGeXNCVkeHUh?=
IMR-5	M2D3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;NcWlEPTB;MT6xOlk{PiEQvF2=	NXfoSXdKW0GQR1XS
ARH-77	NYXlZ\|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTFwMkK5NlQh\|ryP	NET3UWZUSU6JRWK=
BHT-101	M1z6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPLTWM2OD1zLkKzOFkh\|ryP	MmPEV2FPT0WU
SCC-25	NET5NlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPzU2xJUUN3ME2xMlI{PTN4IN88US=>	Mo\XV2FPT0WU
NTERA-S-cl-D1	NHLhWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml;STWM2OD1zLkK0N\|Q3KM7:TR?=	MkO5V2FPT0WU
MKN28	NYPtZZhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LJemlEPTB;MT6yOVY{PiEQvF2=	M4\nUHNCVkeHUh?=
KS-1	M2nUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTFwMkiyOlkh\|ryP	NFPw[4hUSU6JRWK=
NCI-H1734	M1jWXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXXc4dtUUN3ME2xMlI5QTF\|IN88US=>	Mkj6V2FPT0WU
ES7	NFv4UVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzPUY9KSzVyPUGuNlk2PDJizszN	MXzTRW5ITVJ?
NCI-H838	MlGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1W0dWlEPTB;MT6zNFYyPSEQvF2=	MmHpV2FPT0WU
HEC-1	NHjCUZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTFwM{O3OVUh\|ryP	M2W0W3NCVkeHUh?=
ME-180	NIfGcGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PO[WlEPTB;MT6zO\|k6OyEQvF2=	MX\TRW5ITVJ?
MMAC-SF	MljBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTFwM{m1PVUh\|ryP	NVnKNVU1W0GQR1XS
IA-LM	MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTFwNEC5NVQh\|ryP	MWjTRW5ITVJ?
MN-60	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1rTdWlEPTB;MT60N\|EyPCEQvF2=	NVHabJZ4W0GQR1XS
SIMA	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFj2Z3pKSzVyPUGuOFg3QDdizszN	M1nZdHNCVkeHUh?=
NCI-H1770	NXvBRXRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTFwNUKwOVQh\|ryP	NXfyV2s5W0GQR1XS
ONS-76	NUj2WGtsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUW1fJZCUUN3ME2xMlUzOzFzIN88US=>	NEPofXpUSU6JRWK=
LB771-HNC	NYi1OJhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTFwNUO5NFYh\|ryP	NFzhRpZUSU6JRWK=
SW48	NWPkWGlZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWS4OHNlUUN3ME2xMlU1OjR\|IN88US=>	MXvTRW5ITVJ?
KYSE-140	NXvnfHh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjX[\|FRUUN3ME2xMlU2PzRzIN88US=>	NWrFUpJqW0GQR1XS
SW626	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTkTWM2OD1zLkW4NVYh\|ryP	MkTFV2FPT0WU
MC-CAR	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NU\ze3MzUUN3ME2xMlU5PjZ\|IN88US=>	NGO5cHJUSU6JRWK=
D-336MG	M3TPd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;DemlMUUN3ME2xMlYzQTRizszN	NXLhR\|dJW0GQR1XS
SK-MEL-3	NFS0Tm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7PeYZKSzVyPUGuOlM6ODJizszN	MmDlV2FPT0WU
MHH-PREB-1	NHLnR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULkOXpsUUN3ME2xMlY1PDd\|IN88US=>	NVuwUoFpW0GQR1XS
Calu-1	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHsfVU1UUN3ME2xMlY2Ozh4IN88US=>	MleyV2FPT0WU
HCC1806	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTWXHhKSzVyPUGuOlY3OTFizszN	M33y[HNCVkeHUh?=
A101D	NG\YSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTFwNk[3PFEh\|ryP	MVnTRW5ITVJ?
A704	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NECwWnBKSzVyPUGuOlg{OTFizszN	NHfBWlVUSU6JRWK=
LB831-BLC	M4n0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEC2fIpKSzVyPUGuOlk5PTRizszN	MkP6V2FPT0WU
RL95-2	NEHuSG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGf0OJVKSzVyPUGuO\|E1PjNizszN	MWrTRW5ITVJ?
RPMI-2650	M3viRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm[wTWM2OD1zLkeyO\|E6KM7:TR?=	M{jDRnNCVkeHUh?=
NH-12	NGixTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zLOWlEPTB;MT63N\|QzPyEQvF2=	MnKzV2FPT0WU
AGS	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\UTWM2OD1zLke2N\|U5KM7:TR?=	NIDYPGpUSU6JRWK=
NEC8	Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmWwTWM2OD1zLke4PVk2KM7:TR?=	M4jBS3NCVkeHUh?=
NCI-H2009	NX\Qe3pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\sd2lEPTB;MT63PVczOSEQvF2=	Ml7BV2FPT0WU
A498	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TkbmlEPTB;MT64NVI5OiEQvF2=	NF;4N3JUSU6JRWK=
NCI-H810	NWXSWJpsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFwOEG2NFYh\|ryP	MlvBV2FPT0WU
SK-NEP-1	MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTFwOEO3Olch\|ryP	MVLTRW5ITVJ?
D-542MG	MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkH5TWM2OD1zLki1PFUyKM7:TR?=	MUjTRW5ITVJ?
KNS-42	Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUPJR\|UxRTFwOE[yOlYh\|ryP	NFnkUlZUSU6JRWK=
NCI-H2452	NIXQZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDSfXlwUUN3ME2xMlg6ODd2IN88US=>	NUjYdY9rW0GQR1XS
SK-MEL-2	NVi0XYVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rEU2lEPTB;MT65NFI4OSEQvF2=	NHjrTHRUSU6JRWK=
OVCAR-5	M4DzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTFwOUC2O\|Uh\|ryP	NWXVTXNoW0GQR1XS
SNG-M	NFfzfZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT4TWM2OD1zLkm1PFU5KM7:TR?=	Mon2V2FPT0WU
A673	NXW2O\|dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3m0W2lEPTB;MT65O\|UyPiEQvF2=	M4T0cnNCVkeHUh?=
L-428	M4LYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;hb4FvUUN3ME2xMlk6OTd7IN88US=>	Mn3pV2FPT0WU
KM-H2	NITITpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTJwMEGwPUDPxE1?	MmfEV2FPT0WU
MC-IXC	MlnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTiepdoUUN3ME2yMlAzOjd\|IN88US=>	MW\TRW5ITVJ?
COLO-678	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXGxTGRuUUN3ME2yMlA1OjB5IN88US=>	M{KyO3NCVkeHUh?=
MEL-JUSO	Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDSWY9tUUN3ME2yMlA4QDVzIN88US=>	M2jmd3NCVkeHUh?=
HCC38	NG\rRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjVbnpkUUN3ME2yMlA5PDN\|IN88US=>	M3[2N3NCVkeHUh?=
UACC-62	M3PGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrsTWM2OD1{LkC4PFU2KM7:TR?=	NVTBPZM5W0GQR1XS
OAW-42	NHTYeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LtWWlEPTB;Mj6wPVcyOSEQvF2=	MnvRV2FPT0WU
LB996-RCC	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrhTWM2OD1{LkGzPFE4KM7:TR?=	MXfTRW5ITVJ?
COR-L105	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTJwMU[zO\|Mh\|ryP	NI\0W\|dUSU6JRWK=
RCC10RGB	NGr6bItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVizPGJKUUN3ME2yMlE5PTd4IN88US=>	M3S0PHNCVkeHUh?=
A431	M1XId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLVTWM2OD1{LkG5NFE6KM7:TR?=	MVvTRW5ITVJ?
NCI-H292	NUSySIdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV74VXljUUN3ME2yMlI{QTVzIN88US=>	NEDWUJdUSU6JRWK=
SK-UT-1	NU\ZVXFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\6SZBUUUN3ME2yMlM{OTh2IN88US=>	MVfTRW5ITVJ?
PANC-08-13	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoriTWM2OD1{LkOzNlM2KM7:TR?=	MYPTRW5ITVJ?
ST486	NHz3U4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrPcZRKSzVyPUKuOFExPDhizszN	MWTTRW5ITVJ?
SJSA-1	NWDTWZJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;HTWM2OD1{LkSxNlcyKM7:TR?=	NILHflNUSU6JRWK=
RKO	NGrFPJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTJwNEKwNlkh\|ryP	M3LZbnNCVkeHUh?=
NCI-H1793	NEO1S2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkCwTWM2OD1{LkS0NFI6KM7:TR?=	M1zwVnNCVkeHUh?=
639-V	MlmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TIV2lEPTB;Mj60OVM5OiEQvF2=	MXXTRW5ITVJ?
ES3	NHvENm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUDDRnJPUUN3ME2yMlQ6PzN5IN88US=>	MVTTRW5ITVJ?
NCI-H1792	NHHseFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2m2dWlEPTB;Mj61OlgzPiEQvF2=	NUnkbYE1W0GQR1XS
NCI-H1651	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTJwNUiyNUDPxE1?	MUjTRW5ITVJ?
SN12C	NWPpUGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXzJR\|UxRTJwNUi0PFch\|ryP	NGnhXIFUSU6JRWK=
COLO-679	NHH5TJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEjUUFRKSzVyPUKuOVg3ODVizszN	MVnTRW5ITVJ?
U-118-MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17DVGlEPTB;Mj61PFg4OiEQvF2=	M4XhOHNCVkeHUh?=
Ramos-2G6-4C10	NXT5PVdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTJwNkS4NFch\|ryP	NVnRdpZJW0GQR1XS
HCT-15	NHXSZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLtfFRKSzVyPUKuOlg4QTJizszN	NWjG[\|BKW0GQR1XS
MDA-MB-157	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGftXnNKSzVyPUKuO\|A4PDdizszN	NVmyT2dFW0GQR1XS
K5	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTtbm5LUUN3ME2yMlcyQDR3IN88US=>	NVHpemVyW0GQR1XS
MKN45	NWjRbXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjId\|hKSzVyPUKuO\|M{PjZizszN	NELMPW5USU6JRWK=
DMS-273	M4DIVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTJwN{W2N\|Ih\|ryP	MlOyV2FPT0WU
C8166	NInNdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvYTWM2OD1{Lke4OVE{KM7:TR?=	MnTWV2FPT0WU
Calu-3	NU\tfJpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\VNY5KSzVyPUKuO\|g6PjlizszN	M3SyOnNCVkeHUh?=
SNB75	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTJwOEi1N\|Uh\|ryP	NIfUfItUSU6JRWK=
BFTC-905	NI\QU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHFTWM2OD1{LkmwNVkyKM7:TR?=	MlW5V2FPT0WU
C-4-II	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\BTmlEPTB;Mj65NVM2OyEQvF2=	MmXtV2FPT0WU
MS-1	NV[wSXNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFT5S5BKSzVyPUKuPVY4PjlizszN	Mn\TV2FPT0WU
A375	MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrBTWM2OD1\|LkC4NVg1KM7:TR?=	NXXjWIVCW0GQR1XS
KYSE-70	NW\LU5JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEThPHJKSzVyPUOuNFg5QDJizszN	M3SzdnNCVkeHUh?=
KYSE-510	NXvMXmFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT6bIRQUUN3ME2zMlExQTl3IN88US=>	NXflXXQ1W0GQR1XS
LN-405	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TiOmlEPTB;Mz6xN\|UyQCEQvF2=	NFHhUmdUSU6JRWK=
BOKU	Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1O3TGlEPTB;Mz6xOFI2PiEQvF2=	Mln1V2FPT0WU
TE-10	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HmcmlEPTB;Mz6xO\|M3OiEQvF2=	MVHTRW5ITVJ?
MKN1	NWfYfmlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnDRppKSzVyPUOuNVg1QDNizszN	MmTNV2FPT0WU
M059J	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XyXWlEPTB;Mz6yNFE4OyEQvF2=	MkK5V2FPT0WU
GOTO	NFSzOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTNwMkKwN\|kh\|ryP	MYHTRW5ITVJ?
DK-MG	M3LjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPWWoNKSzVyPUOuNlU6PzZizszN	NWTIUlNqW0GQR1XS
NCI-H727	NWDWVokzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDzSJFKSzVyPUOuNlY2QCEQvF2=	NXjPeHZJW0GQR1XS
NB12	NWDzWXlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHn3UlRKSzVyPUOuN\|MzOjRizszN	NF;6RlNUSU6JRWK=
DOK	NWnXW29{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVG4O4R2UUN3ME2zMlM3OTh4IN88US=>	MUjTRW5ITVJ?
KYSE-410	NFTUXlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHPTWM2OD1\|LkO2Nlg4KM7:TR?=	NHP3dXFUSU6JRWK=
AM-38	M2GzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jVVGlEPTB;Mz6zPFA2OSEQvF2=	M1LP[nNCVkeHUh?=
GR-ST	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{fWVGlEPTB;Mz60OVc{OiEQvF2=	MnTmV2FPT0WU
D-247MG	NUP5T\|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTNwNEiyOlMh\|ryP	MkTEV2FPT0WU
TE-8	NH35SndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvYeYNKSzVyPUOuOFk{OzNizszN	MmjlV2FPT0WU
LS-411N	MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPiSY1KSzVyPUOuOFk3QTJizszN	M{fYTHNCVkeHUh?=
SK-MES-1	NUDubVBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYPJR\|UxRTNwNU[0N\|Mh\|ryP	MYLTRW5ITVJ?
SF295	NF;LPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPhXWlKSzVyPUOuOlE2PTJizszN	M{f5VHNCVkeHUh?=
SK-MEL-30	NHv0cldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3ztNmlEPTB;Mz62OVkzOSEQvF2=	NUPuWoNbW0GQR1XS
LB2241-RCC	M{XvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTLelg4UUN3ME2zMlY3OjZizszN	NFfNOW5USU6JRWK=
PC-14	NWHpc2JCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj5RW4yUUN3ME2zMlY3PDN5IN88US=>	NVrDVnUzW0GQR1XS
EW-7	NHXhPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWXifHJmUUN3ME2zMlY4Pjl\|IN88US=>	M2LkXXNCVkeHUh?=
NMC-G1	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTNwN{G4N\|ch\|ryP	MnjHV2FPT0WU
TE-441-T	M{LSXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3WWWJXUUN3ME2zMlc{ODJ6IN88US=>	NETTNnVUSU6JRWK=
NCI-H1618	NYf0U2htT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M13jWGlEPTB;Mz64NVg4PSEQvF2=	MluyV2FPT0WU
PANC-03-27	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTNwOEG5NVYh\|ryP	MnHwV2FPT0WU
NCI-H2228	NVHidGJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfrSWpKSzVyPUOuPFMyOjZizszN	NV3HcHZoW0GQR1XS
CAPAN-1	M1zsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPPR5FzUUN3ME2zMlg4ODB7IN88US=>	NX;SVmdTW0GQR1XS
KLE	NGriSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1npVmlEPTB;Mz65NFY4KM7:TR?=	MUTTRW5ITVJ?
Becker	NWnMcZo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4n2WWlEPTB;Mz65Nlg1QSEQvF2=	MmTLV2FPT0WU
SK-PN-DW	NIDM[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfITWM2OD12LkC3PVc1KM7:TR?=	MlyzV2FPT0WU
Hs-578-T	NHj1eWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnOTWM2OD12LkC4N\|A3KM7:TR?=	NEjQfnNUSU6JRWK=
RS4-11	NX7UfZBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPsfFViUUN3ME20MlEyOjV3IN88US=>	NXjYeZA1W0GQR1XS
D-502MG	MnfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkW2TWM2OD12LkG2PVk4KM7:TR?=	MmHJV2FPT0WU
GI-1	NX\BeoFyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTRwMkiyPVkh\|ryP	NGDlR5RUSU6JRWK=
NCI-H209	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF24VJNKSzVyPUSuN\|M4QCEQvF2=	MYPTRW5ITVJ?
SK-OV-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Moq1TWM2OD12LkS4NVQ6KM7:TR?=	M2DZVXNCVkeHUh?=
LOUCY	Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDkU2FOUUN3ME20MlQ5PDN{IN88US=>	M1zjdnNCVkeHUh?=
NCI-H69	M4fySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf5PFhvUUN3ME20MlUyPzl\|IN88US=>	NYqwfodpW0GQR1XS
SCC-9	MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDoNoE1UUN3ME20MlU{OTd{IN88US=>	MXLTRW5ITVJ?
NCI-H526	NWDrfGNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTvTmp[UUN3ME20MlU6Ojl\|IN88US=>	MlnSV2FPT0WU
NCI-H2170	MnjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXqdVlGUUN3ME20MlY3PzdzIN88US=>	MXnTRW5ITVJ?
SR	M3SzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nteGlEPTB;ND63NFA1QCEQvF2=	MUTTRW5ITVJ?
CMK	NEnvZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTRwN{KxNFEh\|ryP	M4nLdHNCVkeHUh?=
COLO-829	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPVWmxHUUN3ME20Mlc4ODR\|IN88US=>	NGTvNJdUSU6JRWK=
HuO-3N1	NE\GV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfZSIJrUUN3ME20Mlg{OjhzIN88US=>	MV7TRW5ITVJ?
5637	NX\qUmxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTRwOUC0PFch\|ryP	NFXpc2FUSU6JRWK=
A253	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF20d4NKSzVyPUSuPVc4ODhizszN	NHnGU\|hUSU6JRWK=
NB10	NYnvPHd6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEX1[oZKSzVyPUWuNFc1QTdizszN	NX\TOVhTW0GQR1XS
SF539	M1\xR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHRfZNKSzVyPUWuNFk6PTlizszN	NELKbXdUSU6JRWK=
HAL-01	NIWzSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHrVHpKSzVyPUWuNVQ3PDVizszN	MVrTRW5ITVJ?
MHH-ES-1	NXjYOHo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PNUmlEPTB;NT6xOlkzPSEQvF2=	NUHobppkW0GQR1XS
DEL	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTVwMke1PFIh\|ryP	NHHGW\|ZUSU6JRWK=
NCI-H1299	MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX;JR\|UxRTVwM{WwNFch\|ryP	MlPPV2FPT0WU
ChaGo-K-1	NXj6c29KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTVwM{WxNFch\|ryP	NIHF[odUSU6JRWK=
HMV-II	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXRTWM2OD13LkO5OFMh\|ryP	M1rrdnNCVkeHUh?=
NB69	NFTKd5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:xTWM2OD13LkO5OlMyKM7:TR?=	NHq5V2hUSU6JRWK=
NCI-H1882	MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTJRo9IUUN3ME21MlQ{OzZ2IN88US=>	MlX2V2FPT0WU
SNU-475	NIDaPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfvfnVZUUN3ME21MlQ4OTdzIN88US=>	NWrTcZFIW0GQR1XS
RXF393	Mn\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HGWmlEPTB;NT60PFQ6PCEQvF2=	MoLHV2FPT0WU
CAL-51	MmPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\5UmlEPTB;NT62Nlg2OyEQvF2=	M2H0cXNCVkeHUh?=
SW1573	NXXKTWduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTVwNkO1N\|Qh\|ryP	NWXid5NyW0GQR1XS
GCT	NXj1NVd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f5NWlEPTB;NT63OVkzQSEQvF2=	NHiyU5BUSU6JRWK=
COR-L88	NEHRbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTJTWM2OD13Lke2PFQ3KM7:TR?=	M1\kcXNCVkeHUh?=
MDA-MB-134-VI	NYj6TnBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlzQTWM2OD13Lki3OVM3KM7:TR?=	MWrTRW5ITVJ?
NB5	NYXtfXhKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HDSGlEPTB;NT65NlQ1KM7:TR?=	NUjvRnFDW0GQR1XS
GMS-10	M1fJSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXyXXM{UUN3ME21Mlk3QDZzIN88US=>	NVvpbldDW0GQR1XS
CHP-212	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTZwNEiyOlch\|ryP	NH;ab2hUSU6JRWK=
TE-11	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnDS3FqUUN3ME22MlU2OTh{IN88US=>	NYX5N4ZVW0GQR1XS
SW962	NWq5XWpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1y1N2lEPTB;Nj62OVc4PCEQvF2=	Ml3DV2FPT0WU
MZ2-MEL	MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrER5ZHUUN3ME22MlgzODFzIN88US=>	NYnsT29rW0GQR1XS
C-33-A	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILIOYdKSzVyPU[uPVE3QDhizszN	NHviWlNUSU6JRWK=
IGR-1	M3;ZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\HcGlEPTB;Nj65O\|gzPiEQvF2=	MljLV2FPT0WU
MOLT-4	M{S5SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;4TWM2OD15LkG1OFA3KM7:TR?=	NE\uXmFUSU6JRWK=
NCI-H1650	NVruOmN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF7MVFNKSzVyPUeuNlcxPDZizszN	NFfnTpBUSU6JRWK=
AsPC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\6UpNkUUN3ME23MlI5PjB3IN88US=>	MlTtV2FPT0WU
SNU-C2B	NWfjW3RNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\jcGlEPTB;Nz6yPVU4OSEQvF2=	NGLubYRUSU6JRWK=
MKN7	MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4Pae2lEPTB;Nz6zO\|I{PSEQvF2=	NVLOcXk{W0GQR1XS
SW620	NYHXS283T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLoT5VkUUN3ME23MlM5OjB3IN88US=>	MkDKV2FPT0WU
SK-MEL-28	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUHXe3VCUUN3ME23MlQxPzl6IN88US=>	MVTTRW5ITVJ?
TE-6	MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{Phc2lEPTB;Nz60OFkxQCEQvF2=	M2DFRnNCVkeHUh?=
D-263MG	NIn0cIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlf3TWM2OD15LkS1O\|YzKM7:TR?=	M173PXNCVkeHUh?=
NCI-H1355	NHPjSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTdwN{ewNlkh\|ryP	MkG0V2FPT0WU
DSH1	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIe3bWdKSzVyPUeuO\|k4PjJizszN	MX;TRW5ITVJ?
NCI-H460	NH\sOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\lTWM2OD16LkCwOlk1KM7:TR?=	NXKzOGJuW0GQR1XS
NCI-H1563	MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRThwMEe1NFgh\|ryP	MYXTRW5ITVJ?
SW948	NGLoUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7VTWM2OD16LkGwO\|Q1KM7:TR?=	MYnTRW5ITVJ?
LK-2	NFTtW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrC[3pKSzVyPUiuNVI5OzNizszN	NGfs[pdUSU6JRWK=
HT-1080	M4W2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX;JR\|UxRThwMUOxO\|Uh\|ryP	NX;5cmlqW0GQR1XS
NCI-H441	NVHXSXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fhZWlEPTB;OD6xPVMh\|ryP	MkP1V2FPT0WU
HSC-4	NUTwXJJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFuyN4hKSzVyPUiuNlg4OiEQvF2=	M1[3eHNCVkeHUh?=
LXF-289	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRThwM{W5OFMh\|ryP	MXzTRW5ITVJ?
MRK-nu-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFO2dGlKSzVyPUiuN\|Y{ODRizszN	NWDENlB4W0GQR1XS
no-11	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVL3VVhOUUN3ME24MlQ4OTN\|IN88US=>	MXLTRW5ITVJ?
SNU-387	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPKWopjUUN3ME24MlY{OjR4IN88US=>	M3L5S3NCVkeHUh?=
Detroit562	NXjvT2pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP1TWM2OD16Lke1OFU2KM7:TR?=	MlziV2FPT0WU
SW954	M2rNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTtTWM2OD16Lke2PFMzKM7:TR?=	MoXNV2FPT0WU
P12-ICHIKAWA	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\rfWlEPTB;OD63PFk1KM7:TR?=	NYXXWpRvW0GQR1XS
TE-9	MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRThwOEGwOlIh\|ryP	MVnTRW5ITVJ?
NB13	M3LvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXBTWM2OD16LkizO\|k3KM7:TR?=	MmrkV2FPT0WU
BPH-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRThwOEWwPFEh\|ryP	NVTXWlYyW0GQR1XS
KMOE-2	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mke1TWM2OD16Lki3PFkzKM7:TR?=	NES4NGFUSU6JRWK=
RPMI-8402	M1rlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnKTG1nUUN3ME24Mlg6QTJ4IN88US=>	MXjTRW5ITVJ?
OVCAR-3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkK0TWM2OD16Lkm3O\|MzKM7:TR?=	NIr3WHVUSU6JRWK=
NCI-H2196	NVX1TVhtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRThwOUi2NFYh\|ryP	MojoV2FPT0WU
MZ7-mel	NGLiVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDFTWM2OD17LkCzOFYh\|ryP	M4P4cnNCVkeHUh?=
GP5d	NIP1No1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfJOZJKSzVyPUmuNFY{OTNizszN	MX3TRW5ITVJ?
NCI-N87	NEi5[IdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGW5bYlKSzVyPUmuOFQ4OzFizszN	M3XZcXNCVkeHUh?=
EW-16	NEHiSmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTlwNES4OFgh\|ryP	M2fmbnNCVkeHUh?=
Calu-6	NXjjXYZmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\KVmcyUUN3ME25MlQ6PzB\|IN88US=>	MnnwV2FPT0WU
LC4-1	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mor6TWM2OD17Lk[yOVch\|ryP	NWTJbHdwW0GQR1XS
CCRF-CEM	NVviU5pMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;CemlEPTB;OT62PFc3PiEQvF2=	MV7TRW5ITVJ?
BC-1	M2PjcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTlwN{i5PUDPxE1?	NVHwSFhrW0GQR1XS
NCI-SNU-16	MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYP6d4p4UUN3ME25Mlc6PDl3IN88US=>	Mk\UV2FPT0WU
NCI-H28	NXvvNokyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnQOlF2UUN3ME25Mlg1QTN\|IN88US=>	M37pfXNCVkeHUh?=
SBC-1	NWHYTodUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4K3VmlEPTB;MUCuNFczKM7:TR?=	NFvLV21USU6JRWK=
TUR	M3PMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjHTWM2OD1zMD6xOlU4KM7:TR?=	MmLSV2FPT0WU
MDA-MB-231	NHjRfWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofETWM2OD1zMD6yNVE1KM7:TR?=	NHGxUoFUSU6JRWK=
C3A	M2HzNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4Sy[WlEPTB;MUCuN\|E4QSEQvF2=	MnyyV2FPT0WU
SW1990	NW[yVphUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLRTWM2OD1zMD6zNlgh\|ryP	MXfTRW5ITVJ?
NCI-H1993	Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zIV2lEPTB;MUCuOVY6OyEQvF2=	M37ORXNCVkeHUh?=
SK-CO-1	M1m2Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPDd41xUUN3ME2xNE44PzdizszN	NG\CS\|FUSU6JRWK=
OAW-28	NHzOO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLsOW42UUN3ME2xNE46QDh6IN88US=>	Ml;VV2FPT0WU
HN	NXnX[ZViT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoW1TWM2OD1zMT6xNVMyKM7:TR?=	M3nyeXNCVkeHUh?=
NCI-H1304	NXm5O21JT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\LfGlEPTB;MUGuNVU4PiEQvF2=	M1j3NHNCVkeHUh?=
Daoy	NW\MeJpGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3ITWM2OD1zMT60N\|M3KM7:TR?=	NUTq[nFIW0GQR1XS
VA-ES-BJ	NGDJcXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTFzLkexPVUh\|ryP	NHfmTY5USU6JRWK=
MCF7	NFjpNGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITSNIpKSzVyPUGxMlgyOjZizszN	NIXZUGZUSU6JRWK=
VM-CUB-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmq1TWM2OD1zMT65NFkyKM7:TR?=	Mn\HV2FPT0WU
IPC-298	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4m4b2lEPTB;MUGuPVM5OyEQvF2=	NHTIRo1USU6JRWK=
NCI-H2126	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTF{LkCyNVgh\|ryP	M1jTWHNCVkeHUh?=
OVCAR-8	M2WxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTF{LkGxOFEh\|ryP	MnLHV2FPT0WU
SJRH30	M2jsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTF{LkKyPVkh\|ryP	M3vqOXNCVkeHUh?=
DMS-53	NFPndm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTF{LkK2OFkh\|ryP	NGq3bI1USU6JRWK=
NCI-H322M	MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mkn6TWM2OD1zMj6zN\|U4KM7:TR?=	NHX1bppUSU6JRWK=
RVH-421	M4\hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfO[FhXUUN3ME2xNk41QTB2IN88US=>	MVjTRW5ITVJ?
Raji	NXPUXnVpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jZZ2lEPTB;MUKuOlE1KM7:TR?=	NVy0Z4VpW0GQR1XS
MDA-MB-415	NXvuO25FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEL4NVFKSzVyPUGyMlY1PDRizszN	NXq0OYNyW0GQR1XS
EFE-184	NF;ydZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTF{LkexNFYh\|ryP	NF\wTZhUSU6JRWK=
BFTC-909	NHzr[5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrWb49pUUN3ME2xNk46OjR5IN88US=>	NHnGbYhUSU6JRWK=
BHY	M{f6NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTF\|LkOzPUDPxE1?	MlGyV2FPT0WU
YKG-1	M1HtPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTF\|LkO3OFkh\|ryP	Mm[5V2FPT0WU
EW-3	NVfZPHVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnv[W1MUUN3ME2xN{44OTZ\|IN88US=>	MoLjV2FPT0WU
HCC1143	MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2T5e2lEPTB;MUOuO\|Q{PyEQvF2=	NXTiOnZmW0GQR1XS
REH	NWPkV4pDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTF\|Lki5PFIh\|ryP	M1S4[HNCVkeHUh?=
CESS	NYq1U\|RxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\LPGlEPTB;MUOuPVQ5QSEQvF2=	NHzwOVhUSU6JRWK=
EFM-19	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYiyZY9DUUN3ME2xOE4yOTF{IN88US=>	NV\Jb486W0GQR1XS
U031	NH3n[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTF2LkSwPFUh\|ryP	MYXTRW5ITVJ?
ES1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI[3TYpKSzVyPUG0MlQ5PTFizszN	MVvTRW5ITVJ?
HSC-3	NV7oNnR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLrTWM2OD1zND62NlE2KM7:TR?=	NYqy[HVWW0GQR1XS
LOXIMVI	M1\G[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTF2LkewOlgh\|ryP	MlrFV2FPT0WU
A388	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mon3TWM2OD1zND63OVU3KM7:TR?=	Mlv4V2FPT0WU
KP-N-YS	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HVcWlEPTB;MUSuO\|c{KM7:TR?=	MknyV2FPT0WU
Capan-2	NIjvcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTF2Lke4OkDPxE1?	NW\zSYU6W0GQR1XS
SKG-IIIa	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TofmlEPTB;MUSuPFg3OiEQvF2=	M{jVTnNCVkeHUh?=
HEL	M4XESGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPI[2xKSzVyPUG0Mlg6QTdizszN	M2GzdXNCVkeHUh?=
BEN	NGGyc5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlrLTWM2OD1zND65O\|Y3KM7:TR?=	M1[zNXNCVkeHUh?=
MC116	NXnTT5lPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1X3fGlEPTB;MUWuNVU6QSEQvF2=	NXewO5BmW0GQR1XS
IGROV-1	NUn4S4pHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjQ[llKSzVyPUG1MlI{OTdizszN	M2\lRnNCVkeHUh?=
NCI-H1648	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;DenIyUUN3ME2xOU42OzB3IN88US=>	MVrTRW5ITVJ?
ABC-1	M4mxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWrJR\|UxRTF3LkiwN\|Mh\|ryP	MkHGV2FPT0WU
EW-18	NGLNXlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGruenVKSzVyPUG1Mlk6PzlizszN	MYnTRW5ITVJ?
BC-3	M1SxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7WSVloUUN3ME2xOk4xPTZ{IN88US=>	NGnzOmdUSU6JRWK=
NCI-H1437	M{jpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{j1PWlEPTB;MU[uNFY3PyEQvF2=	MXPTRW5ITVJ?
SCC-15	NH7wc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTF4LkK4NlUh\|ryP	MVPTRW5ITVJ?
TT	Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{C0WGlEPTB;MU[uOVg5QCEQvF2=	MVzTRW5ITVJ?
KINGS-1	MoXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HDOWlEPTB;MU[uPFI4OyEQvF2=	M4\ySnNCVkeHUh?=
C32	NFy0cVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rrXWlEPTB;MU[uPVcyPyEQvF2=	MYnTRW5ITVJ?
SBC-5	NVzBdHVYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLRTWM2OD1zNz6xOFc6KM7:TR?=	NH\CbZpUSU6JRWK=
NB1	MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\ST3ZnUUN3ME2xO{4{OTh6IN88US=>	MW\TRW5ITVJ?
EB-3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnocHdEUUN3ME2xO{42PzZizszN	NILYN\|FUSU6JRWK=
NCI-H748	MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIPVNW9KSzVyPUG3MlcxOzVizszN	Mm\TV2FPT0WU
IST-SL1	M{C3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjWTWM2OD1zNz63OVI3KM7:TR?=	M2HyfXNCVkeHUh?=
WM-115	NWTNOmh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEGwVnJKSzVyPUG3MlgxQDVizszN	MWTTRW5ITVJ?
NCI-H226	M4jrWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTF5Lkm1OFYh\|ryP	M1vYVnNCVkeHUh?=
CAL-33	M4DXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEHm[FlKSzVyPUG4MlI4QDFizszN	Moj4V2FPT0WU
SCC-4	Ml\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlu1TWM2OD1zOD6zNlI6KM7:TR?=	M4exUHNCVkeHUh?=
RMG-I	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XEO2lEPTB;MUiuOlk1PyEQvF2=	NHLGXlRUSU6JRWK=
KOSC-2	NGLDW2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHK1TopKSzVyPUG4Mlc4PDZizszN	M1G1SHNCVkeHUh?=
A2058	MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfFTWM2OD1zOD64NlU2KM7:TR?=	MknyV2FPT0WU
HCC70	NIq5NYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HXSGlEPTB;MUmuN\|g6PCEQvF2=	MUHTRW5ITVJ?
C2BBe1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnSTWM2OD1zOT60NVQ5KM7:TR?=	M3XPcHNCVkeHUh?=
NCI-H650	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXaZlF3UUN3ME2xPU42QDl7IN88US=>	NUjzNJZDW0GQR1XS
CAL-72	MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3:2cmlEPTB;MUmuOlc{PyEQvF2=	M{TZTnNCVkeHUh?=
L-363	NFnPe\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTJyLkCyNVIh\|ryP	NVvkdpBHW0GQR1XS
SNU-423	M4Lkemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV7JR\|UxRTJyLkGwOFMh\|ryP	MnHZV2FPT0WU
PLC-PRF-5	MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrneJJKSzVyPUKwMlM6ODZizszN	MWnTRW5ITVJ?
SW1463	NGj1XIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;rU2lEPTB;MkCuOFUzPSEQvF2=	NGC3N4ZUSU6JRWK=
769-P	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTJyLk[3Olkh\|ryP	NGfocHpUSU6JRWK=
DMS-79	M4XQfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXDN5lqUUN3ME2yNE45PDlizszN	M1jqbHNCVkeHUh?=
Saos-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrFT2xuUUN3ME2yNE46PTV4IN88US=>	NYnESYtnW0GQR1XS
CHP-126	NH;TUXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mor0TWM2OD1{MT60OFYzKM7:TR?=	MWDTRW5ITVJ?
SW837	NIHTUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;uT\|ZMUUN3ME2yNU41QTN7IN88US=>	M{L6dnNCVkeHUh?=
SHP-77	MnqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHv3RYVKSzVyPUKxMlYyOjJizszN	NXvCWnN4W0GQR1XS
DB	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULReIpSUUN3ME2yNU43OTR{IN88US=>	NEPsO4tUSU6JRWK=
ES5	NH2yToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDNW2x[UUN3ME2yNU43QDZ2IN88US=>	M3XxXXNCVkeHUh?=
COR-L23	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zTWmlEPTB;MkGuPFA2OSEQvF2=	NYTFSpZyW0GQR1XS
KU-19-19	MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{H2RmlEPTB;MkGuPFk5OiEQvF2=	MljWV2FPT0WU
T84	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTJzLkm4NVkh\|ryP	M{nofnNCVkeHUh?=
NCI-H630	M33QTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{fTZWlEPTB;MkKuOVM3OyEQvF2=	MkCwV2FPT0WU
LU-165	NXTLcppqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPmXVBDUUN3ME2yNk42PTRizszN	M2\0S3NCVkeHUh?=
COLO-792	NHTmO25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjCV2xJUUN3ME2yNk44OTFzIN88US=>	NIXae3BUSU6JRWK=
CAL-62	MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjUTWM2OD1{Mj63OVE4KM7:TR?=	M3vXdnNCVkeHUh?=
HCE-T	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTJ{Lki2NFYh\|ryP	NUnHendmW0GQR1XS
BB65-RCC	NH\ucHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTJ\|LkCzOFQh\|ryP	MULTRW5ITVJ?
SiHa	MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIX1RYdKSzVyPUKzMlM6PjhizszN	Mn3OV2FPT0WU
NCI-H2081	MmrnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fNcGlEPTB;MkSuNFY1OSEQvF2=	MnvRV2FPT0WU
U251	NV;HOopJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTJ2LkC2Olgh\|ryP	NWHEb4VjW0GQR1XS
LoVo	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJ2LkmyPFIh\|ryP	NEfuNoJUSU6JRWK=
GCIY	NIn1fXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTrTWM2OD1{NT6yPFc4KM7:TR?=	MXvTRW5ITVJ?
NUGC-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\OTWM2OD1{NT6zN\|E3KM7:TR?=	NHLNZplUSU6JRWK=
LNCaP-Clone-FGC	NX\1WIdkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3u1R2lEPTB;MkWuN\|Q6QCEQvF2=	NXW5eYo5W0GQR1XS
PA-1	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2S1T2lEPTB;MkWuOlg{OyEQvF2=	NVOxcm1nW0GQR1XS
OE33	M4\6T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\RS29KSzVyPUK1MlY5PTNizszN	M3rGSHNCVkeHUh?=
HT-29	NIfhVHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFu1T3VKSzVyPUK1Mlc5PzlizszN	MmDzV2FPT0WU
RCM-1	NHHkbGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DQS2lEPTB;MkWuPVY2PiEQvF2=	M4\VT3NCVkeHUh?=
NCI-H1522	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2XPUmlEPTB;MkWuPVkyOSEQvF2=	MVrTRW5ITVJ?
LB373-MEL-D	M1vacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnZbY5vUUN3ME2yOk4yPzB6IN88US=>	NIT3cGxUSU6JRWK=
NCI-H1436	M1TpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTJ4LkK3N\|gh\|ryP	NWL2N205W0GQR1XS
COLO-824	M3q5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\lTYViUUN3ME2yOk41ODB{IN88US=>	Mn\kV2FPT0WU
CP50-MEL-B	NFO4c4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoSwTWM2OD1{Nj61Olc2KM7:TR?=	NWfLfWxGW0GQR1XS
EGI-1	MnHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTJ5LkK2PVgh\|ryP	MlSyV2FPT0WU
LAN-6	MmDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3jJNGlEPTB;MkeuN\|U6QCEQvF2=	NIPrUGVUSU6JRWK=
GAK	NHXPN5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTJ5LkSyNlUh\|ryP	MUPTRW5ITVJ?
MDA-MB-175-VII	NWmzcZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEO0XHhKSzVyPUK3MlUxPTNizszN	MkjuV2FPT0WU
JVM-2	Ml:3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvxdpU3UUN3ME2yO{43PjJ{IN88US=>	NUjjPWZCW0GQR1XS
UACC-257	MlfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\Re\|RCUUN3ME2yO{43QDd6IN88US=>	M1\reXNCVkeHUh?=
SW1783	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYDJR\|UxRTJ5Lke3PFMh\|ryP	MkPWV2FPT0WU
HT-3	M3XzZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P6XGlEPTB;MkiuNlE3PiEQvF2=	M4HRO3NCVkeHUh?=
RL	NH\SSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2XDOGlEPTB;MkiuOVkyOSEQvF2=	NIm3[ZdUSU6JRWK=
TK10	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DYcWlEPTB;MkiuOlU{PSEQvF2=	M3K3Z3NCVkeHUh?=
HT55	NIXa[4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTJ7LkC1OlUh\|ryP	NW\oZplrW0GQR1XS
BT-20	NWrIOWpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTJ7LkC1PFYh\|ryP	MUXTRW5ITVJ?
TGBC24TKB	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTJ7LkG4N\|Eh\|ryP	MmLzV2FPT0WU
HSC-2	NWK5PVFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjwUm9CUUN3ME2yPU4{ODBzIN88US=>	M{\IcXNCVkeHUh?=
COLO-205	MoXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjGbpVKSzVyPUK5MlM6PDRizszN	NGrqTopUSU6JRWK=
GT3TKB	NGrZcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTJ7Lk[4O\|ch\|ryP	MX7TRW5ITVJ?
T47D	MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTJ7Lki1PFIh\|ryP	NYX6XHl4W0GQR1XS
OMC-1	M{nIdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HjNmlEPTB;M{CuNVkyQSEQvF2=	MYnTRW5ITVJ?
PFSK-1	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvEb5hKSzVyPUOxMlI3PTlizszN	MnXBV2FPT0WU
JEG-3	NYHRe2NFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\rVpdKSzVyPUOxMlM2PjFizszN	MoPUV2FPT0WU
RD	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTNzLkWxNVUh\|ryP	MUHTRW5ITVJ?
NCI-H64	NHvISVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTN{LkSxO\|kh\|ryP	MXPTRW5ITVJ?
DMS-114	NHTnSIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHrIPFNKSzVyPUOyMlQyQDJizszN	MVjTRW5ITVJ?
NCI-H661	NHvDVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTN{Lk[1NFEh\|ryP	NXLkbIpVW0GQR1XS
CAL-148	M1P6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGjpSItKSzVyPUOyMlY3PjVizszN	NEj2fZpUSU6JRWK=
HuP-T3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3XWdGlEPTB;M{KuPVM{QCEQvF2=	MVzTRW5ITVJ?
ES4	NXLMTpZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HxTGlEPTB;M{OuNVcxPSEQvF2=	MYrTRW5ITVJ?
Ca9-22	NUP4UlZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHZXol2UUN3ME2zN{41PjBzIN88US=>	NIfhXGdUSU6JRWK=
LP-1	MkfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPpTWM2OD1\|ND6wPUDPxE1?	MXrTRW5ITVJ?
AU565	NYr1fWxHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nFcWlEPTB;M{SuOVA3QSEQvF2=	MnjNV2FPT0WU
MDA-MB-453	NHTU[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\xeodKSzVyPUO1MlE1OjZizszN	NHPl[lBUSU6JRWK=
SNU-C1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXqTHdVUUN3ME2zOU4yPzFizszN	M1L0T3NCVkeHUh?=
SW13	M1rrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTN3LkSwO\|Yh\|ryP	Ml;UV2FPT0WU
NCI-H2122	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjaTWM2OD1\|NT61OVk5KM7:TR?=	MXzTRW5ITVJ?
NCI-H1395	NHrDOFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXwTWM2OD1\|NT62OlkyKM7:TR?=	MXXTRW5ITVJ?
J-RT3-T3-5	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzvTWM2OD1\|Nj6wNlk1KM7:TR?=	MVLTRW5ITVJ?
COR-L279	Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7NZ\|lKSzVyPUO2MlE6QDFizszN	NGPjfXFUSU6JRWK=
ATN-1	NWrY[mN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLMcXJQUUN3ME2zOk45PTF4IN88US=>	MWHTRW5ITVJ?
HCC2998	NHjrOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV;iO5pFUUN3ME2zOk45PTdzIN88US=>	MWrTRW5ITVJ?
UM-UC-3	M3S5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHS3b5ZKSzVyPUO2Mlg3PzVizszN	NGW2R2RUSU6JRWK=
DV-90	M2naOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml20TWM2OD1\|Nj65NFY4KM7:TR?=	M4TUR3NCVkeHUh?=
ES8	MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHs[YpNUUN3ME2zOk46OzF6IN88US=>	MVHTRW5ITVJ?
YAPC	M3ryN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjzSWJDUUN3ME2zOk46PjV2IN88US=>	NIDhXmpUSU6JRWK=
HCC1599	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnThTWM2OD1\|Nz6xOlE5KM7:TR?=	NFr2RXdUSU6JRWK=
UMC-11	M4HnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnzYTWM2OD1\|Nz6yOVA{KM7:TR?=	MXHTRW5ITVJ?
THP-1	M{fkOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnZVolKSzVyPUO3MlI5PjhizszN	MlLLV2FPT0WU
OCUB-M	NX73OGxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHEfWJKSzVyPUO3MlI5QTFizszN	M4\QO3NCVkeHUh?=
NCI-H1693	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjkTWM2OD1\|Nz6zNlM{KM7:TR?=	M2rtcXNCVkeHUh?=
NCI-H345	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjBfIV5UUN3ME2zO{4{PjJ2IN88US=>	MkTMV2FPT0WU
COLO-800	NHLS[XVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\lO2lEPTB;M{euOVY4KM7:TR?=	NHGzXHBUSU6JRWK=
COLO-320-HSR	MkPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{W3fGlEPTB;M{iuN\|Q6OiEQvF2=	NGPPcZJUSU6JRWK=
NCI-H596	MmLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXuTJlKSzVyPUO4MlQ1QDlizszN	NFL0TVlUSU6JRWK=
NCI-H187	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTN6LkezOFQh\|ryP	NEfC[phUSU6JRWK=
ECC4	M1PxOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MU\JR\|UxRTN7LkC4NVQh\|ryP	NX2xfpVLW0GQR1XS
KP-4	MkX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M322OmlEPTB;M{muNVI{PSEQvF2=	MlzMV2FPT0WU
NCI-H2227	M33iWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\a[WlEPTB;M{muN\|k1QSEQvF2=	NIjMfmJUSU6JRWK=
22RV1	Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHrqRXFKSzVyPUO5Mlg{QThizszN	NWLNV2s1W0GQR1XS
SAS	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTRyLkC5OkDPxE1?	MorXV2FPT0WU
PANC-10-05	MkfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXuc2xKSzVyPUSwMlE5OjhizszN	NHzjb2VUSU6JRWK=
MDA-MB-468	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjZ[WhKSzVyPUSwMlU{PDZizszN	MV7TRW5ITVJ?
RPMI-7951	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTRzLkKwO\|Uh\|ryP	MkPoV2FPT0WU
BB49-HNC	M1nIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTRzLkKxO\|kh\|ryP	NHXHeFRUSU6JRWK=
23132-87	NUPGPWp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUDJR\|UxRTRzLkK3N\|Ih\|ryP	NV7oVlZvW0GQR1XS
HCC1569	NIXDfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzjTWM2OD12MT6yPFg2KM7:TR?=	NHrQSJJUSU6JRWK=
CP66-MEL	M1vLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3hSoVKSzVyPUSyMlE5QDZizszN	NWnUeZExW0GQR1XS
K-562	M3LW[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVziVJF2UUN3ME20Nk4zQDV2IN88US=>	MnW5V2FPT0WU
OCI-AML2	NIDKU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEn2VnVKSzVyPUSyMlg6PzRizszN	NUjiRm1nW0GQR1XS
SW756	M1fBUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTR\|LkCzPFgh\|ryP	M3nXRnNCVkeHUh?=
M14	M{H2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHoZYpDUUN3ME20N{4{OTh7IN88US=>	MYrTRW5ITVJ?
NCI-H1623	NIHmV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHuxZ2VKSzVyPUSzMlQ3PCEQvF2=	Ml\aV2FPT0WU
KNS-81-FD	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnn3TWM2OD12Mz63OlIh\|ryP	NFm3SWRUSU6JRWK=
TGBC1TKB	NEXhO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1q1eGlEPTB;NEOuPVA6QSEQvF2=	M2nlVXNCVkeHUh?=
RERF-LC-MS	M3r3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTR\|LkmyPFEh\|ryP	M2L2e3NCVkeHUh?=
PC-3	M4PoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXBTWM2OD12ND60N\|Q4KM7:TR?=	NYXQTINKW0GQR1XS
HuP-T4	M3rRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTR2LkS0O\|Qh\|ryP	Mn;lV2FPT0WU
NCI-H510A	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHxUI1sUUN3ME20OE44ODhizszN	NI[5Xm5USU6JRWK=
LB2518-MEL	M4Sxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVmxeYZVUUN3ME20OE44QTN5IN88US=>	NFrGd4FUSU6JRWK=
TE-5	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXy3e2Q2UUN3ME20OU46PThzIN88US=>	Mn7GV2FPT0WU
EW-24	NUXJS5hxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHL6XW9KSzVyPUS2MlE4OjNizszN	NYHkcIRDW0GQR1XS
LB647-SCLC	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3PybmlEPTB;NE[uNlE2PSEQvF2=	NVrDTFl5W0GQR1XS
NCI-H524	NF;FcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTR4LkexPFUh\|ryP	M164cHNCVkeHUh?=
EW-11	MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHmZY9pUUN3ME20Ok46Ozd\|IN88US=>	MW\TRW5ITVJ?
KALS-1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nkd2lEPTB;NEeuNlA3PiEQvF2=	NE\mdo1USU6JRWK=
BT-474	M135WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTR5LkSyNVYh\|ryP	NVH4bGhDW0GQR1XS
SK-N-AS	NHvHdFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnT3TWM2OD12Nz64PFgh\|ryP	NYXnPXc5W0GQR1XS
HCC2157	M{DkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPEOlJKSzVyPUS4MlA4PiEQvF2=	M4nMR3NCVkeHUh?=
HCC1954	M2nQV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkT2TWM2OD12OD6xO\|A1KM7:TR?=	M4ixZXNCVkeHUh?=
FADU	M4PuN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HqPWlEPTB;NEiuN\|A{OSEQvF2=	NVvYfYx5W0GQR1XS
S-117	NXi4[Fh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTR6LkO4NVUh\|ryP	NX3iO4ZWW0GQR1XS
LS-1034	MojES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7kelJKSzVyPUS4MlcxPjdizszN	M{HVfnNCVkeHUh?=
CAMA-1	NETTOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXUPHRKSzVyPUS5MlU2PDNizszN	NX\XTpQyW0GQR1XS
LU-134-A	M{nBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\Sd5lpUUN3ME20PU45ODh3IN88US=>	MXPTRW5ITVJ?
NCI-H1838	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjpdmRGUUN3ME20PU45ODh5IN88US=>	M3zScXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pSrc / Src / pPlcg / Plcg / pStat5 / Stat5 ; PubMed: 22781593 Leukemia In (B) inhibition of Src, Plcg and Stat5 was seen in MLNAF cell lines treated with Ponatinib; ZNF112 expresses ZMYM2–FGFR1, CEP2A and CEP5A cells express CEP110–FGFR1 and BBC2 expresses BCR–FGFR1. pFGFR1(pY20) / FGFR1; PubMed: 22781593 Leukemia Western blot analysis, using various antibodies specific for downstream targets of FGFR1, demonstrates that Ponatinib inhibits the activation of Plcg and Src as a result of inhibiting the FGFR1 fusion kinase in human KG1 cells. cleaved caspase-3 / cleaved caspase-7 / BAX / Bcl-2; PubMed: 30959969 Molecules Western blot analysis of cleaved caspase-3, cleaved caspase-7, Bax, Bcl-2, and β-Tubulin (control) in treated cells. p-Rb(S807/811) / Rb / CDK4 / CDK6 / Cyclin D1 / CDK2 / Cyclin E1; PubMed: 30959969 Molecules Western blot analysis of Rb/p-Rb, CDK4, CDK6, Cyclin D1, CDK2, Cyclin E1, and β-Tubulin (control) in the SK-Hep-1 and SNU-423 cells treated with ponatinib. RAD51; PubMed: 30959969 Molecules The effect of ponatinib on the concentration of Rad51 in SK-Hep-1 and SNU-423 cells. p-MEK / MEK / p-ERK / ERK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Mek and Erk. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. c-Jun / p-JNK(T183/Y185) / JNK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of JNK and c-Jun. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-p38 MAPK / p38 MAPK; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of p38. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. p-JAK2 / JAK2 / p-STAT3 / STAT3; PubMed: 30959969 Molecules Effect of ponatinib on the phosphorylation of Jak2, and Stat3. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a control. PI3K p85 / p-PI3K / p-PDK1 / PDK1 / p-mTOR / mTOR; PubMed: 30959969 Molecules Effects of ponatinib on the protein concentration and phosphorylation of PI 3-kinase, PDK1, Akt, and mTOR in HCC cells. p-PDGFRα / PDGFRα; PubMed: 24472312 Mol Cancer Ponatinib inhibited phosphorylation of PDGFRα in a concentration-dependent manner. EOL-1 and BaF3-WT or -T674I FIP1L1-PDGFRα cells were exposed to escalating concentrations of ponatinib for 24 h. PARP / Caspase-3 / Active Caspase-3; PubMed: 24472312 Mol Cancer The concentration- (for 24 h) and time-dependent (1 nM for EOL-1, 300 nM for BaF3-WT and -T674I FIP1L1-PDGFRα cells) cleavage of PARP and caspase-3 triggered by ponatinib was analyzed by immunoblotting. AIF / Cyto C ; PubMed: 24472312 Mol Cancer Ponatinib elicited release of AIF and cytochrome c into the cytosol. Cells were treated with 1 nM ponatinib for the indicated durations and the cytosolic fraction was extracted with digitonin buffer. Levels of AIF and Cytochrome c (Cyto c) were detected by immunoblotting. Mcl-1 / Survivin / Bcl-Xl / XIAP / Bax / Bcl-2 / Bim; PubMed: 24472312 Mol Cancer Immunoblotting of apoptosis-related proteins in CEL cells after treatment for 24 h. β-catenin ; PubMed: 24472312 Mol Cancer Ponatinib concentration-dependently lowered β-catenin. EOL-1 cells were incubated with ponatinib for 24 h, and cytoplasmic and nuclear extracts were determined by immunoblotting. β-catenin; PubMed: 24472312 Mol Cancer Analysis of β-catenin localization. EOL-1 cells were pretreated with 1 nM ponatinib for 24 h, immunofluorescence analysis was performed with anti-β-catenin. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI). ABL; PubMed: 19878872 Cancer Cell In vitro [γ-32P]-ATP autophosphorylation of full-length (A) ABL or (B) ABLT315I kinase treated with AP24534, imatinib, nilotinib, or dasatinib. After incubation of tyrosine-dephosphorylated enzyme with the indicated inhibitor in the presence of [γ-32P]-ATP and separation by SDS-PAGE, signal intensity was measured by autoradiography.	22781593 30959969 24472312 19878872
Growth inhibition assay	Cell viability; PubMed: 30174789 Oncotarget (A) Effect of Ponatinib on basal viability of HUVECs. The cells were treated with Ponatinib at indicated concentrations or 0.1% DMSO (vehicle control) for 24 h.	30174789

In vivo

In a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl, AP24534 (2.5 mg/kg and 5 mg/kg) prolongs mice median survival. In the xenograft model of Ba/F3 Bcr-Abl^T315I, AP24534 (10 mg/kg–50 mg/kg) significantly suppresses tumor growth. AP24534 (30 mg/kg) decreases the phosphorylated Bcr-Abl and phosphorylated CrkL levels in the tumors. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse Peptide substrate phosphorylation assays with GST-Abl kinase domains: The effect of AP24534 (0-320 nM) on GST-Abl kinase activity is assessed by using a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). Assays are carried out at 30 °C for 15 min in 25 μL reaction mixture: 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl₂, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-³²[P]ATP (5000 cpm/pmol). Reactions are terminated by transferring a portion of the reaction mixture onto a p81 phosphocellulose filter and immersing in 0.75% phosphoric acid. Filters are washed 3 times in 0.75% phosphoric acid, rinsed in acetone, and air dried; phosphate incorporation is determined by scintillation counting. All results are corrected for background binding to the filters, as determined by omitting peptide substrate from the kinase reaction. Time course experiments to establish the linear range of enzymatic activity precedes kinase assays.
Cell Research:^[2]	- Collapse Cell lines: Ba/F3 cells expressing Bcr-Abl or a range of single mutations in the kinase domain of Bcr-Abl Concentrations: 0-625 nM Incubation Time: 72 hours Method: Ba/F3 cell lines are distributed in 96-well plates (4 × 10³ cells/well) and incubated with AP24534 for 72 hours. Proliferation is measured using a methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution). All values are normalized to the control wells with no drug. IC50 values are reported as the mean of three independent experiments performed in quadruplicat (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Mouse xenograft models of Ba/F3 cells expressing Bcr-Abl or Bcr-Abl^T315I Dosages: 2.5 mg/kg and 5 mg/kg for Ba/F3 Bcr-Abl; 2.5 mg/kg–50 mg/kg for Ba/F3 Bcr-Abl^T315I Administration: Oral gavage once daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	30 mg/mL (56.33 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 1% CMC Na For best results, use promptly after mixing.	30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ponatinib (AP24534) SDF

Molecular Weight	532.56
Formula	C₂₉H₂₇F₃N₆O
CAS No.	943319-70-8
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-09-01)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04160546	Recruiting	Drug: Ponatinib 15 MG\|Drug: Acetylsalicylic acid 100 MG	Chronic Myeloid Leukemia Chronic Phase	Fundacion CRIS de Investigación para Vencer el Cáncer\|Incyte Biosciences UK\|Apices Soluciones S.L.	January 17 2020	Phase 2
NCT04070443	Recruiting	Drug: Ponatinib\|Drug: Imatinib	Philadelphia Chromosome Positive CML\|BCR-ABL Positive Chronic Myelogenous Leukemia	Centre Leon Berard	November 13 2019	Phase 2
NCT03934372	Recruiting	Drug: Ponatinib	Acute Myeloid Leukemia\|Accelerated Phase Chronic Myeloid Leukemia\|Blast Phase Chronic Myeloid Leukemia\|Chronic Phase Chronic Myeloid Leukemia\|Acute Lymphoblastic Leukemia\|Acute Lymphocytic Leukemia\|Leukemia\|Lymphoma\|Solid Tumors	Incyte Biosciences International Sàrl\|Incyte Corporation	November 22 2019	Phase 1\|Phase 2
NCT03895671	Recruiting	Drug: Ponatinib\|Drug: Azacitidine	CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE\|CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS	Versailles Hospital	June 19 2019	Phase 2
NCT03690115	Recruiting	Drug: Ponatinib 30 MG	Leukemia Myeloid Acute	Versailles Hospital	December 12 2018	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is the pre-solubilized inhibitor suitable for in vivo whole animal studies? Whether the solvent contains any non-DMSO stabilizer?
Answer:
Our 10mM Ponatinib in DMSO solution is in pure DMSO and there is not other stabilizer added. You can use it for animal study. The vehicle we suggest for Ponatinib is: 30% PEG400/0.5% Tween80/5% Propylene glycol. It is a milky suspension used for oral gavage.

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Selective Bcr-Abl Inhibitor

Nilotinib (AMN-107) : Bcr-Abl-selective, IC50<30 nM.
Most Potent Bcr-Abl Inhibitor

GZD824 : Bcr-Abl(WT), IC50=0.34 nM; Bcr-Abl(T315I), IC50=0.68 nM.
FDA-approved Bcr-Abl Inhibitor

Dasatinib : Approved by FDA for CML and Ph+ ALL.
Newest Bcr-Abl Inhibitor

GZD824 : Orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.

Related Bcr-Abl Products

PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
SU6656 ^New

SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Imatinib Mesylate (STI571)

Imatinib Mesylate (STI571, CGP-57148B) is an orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively. Imatinib Mesylate (STI571) induces autophagy.
Nilotinib (AMN-107)

Nilotinib (AMN-107) is a selective Bcr-Abl inhibitor with IC50 less than 30 nM in Murine myeloid progenitor cells. Nilotinib induces autophagy through AMPK activition.

Features:A selective inhibitor of native and mutant Bcr-Abl.
Bafetinib (INNO-406)

Bafetinib (INNO-406, NS-187) is a potent and selective dual Bcr-Abl/Lyn inhibitor with IC50 of 5.8 nM/19 nM in cell-free assays, does not inhibit the phosphorylation of the T315I mutant and is less potent to PDGFR and c-Kit. Phase 2.

Features:Dual Bcr-Abl/Lyn inhibitor.
Degrasyn (WP1130)

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.

Features:WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Rebastinib (DCC-2036)

Rebastinib (DCC-2036) is a conformational control Bcr-Abl inhibitor for Abl1(WT) and Abl1(T315I) with IC50 of 0.8 nM and 4 nM, also inhibits SRC, LYN, FGR, HCK, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit. Phase 1.

Features:A conformational control inhibitor of Abl1 and T315I Abl1.
GZD824 Dimesylate(HQP1351)

GZD824 Dimesylate (HQP1351) is a novel orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT) and Bcr-Abl(T315I) with IC50 of 0.34 nM and 0.68 nM, respectively.
GNF-2

GNF-2 is a highly selective non-ATP competitive inhibitor of Bcr-Abl, shows no activity to Flt3-ITD, Tel-PDGFR, TPR-MET and Tel-JAK1 transformed tumor cells.

Choose Your Country or Region

By Signaling Pathways

By product type

Ponatinib (AP24534)